IBRX
ImmunityBio Inc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website immunitybio.com
- Employees(FY) 670
- ISIN US45256X1037
Performance
+7.55%
1W
+64.38%
1M
+98.58%
3M
+144.19%
6M
+67.33%
YTD
+160.87%
1Y
Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
Investment Analysis Report: IBRX
Overview
In this investment analysis report, we will delve into the financial statements of IBRX, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating ...
Technical Analysis of IBRX 2024-05-10
Overview:
In analyzing the technical indicators for IBRX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...
Recent News & Updates
- 2024-05-11 08:39
- 2024-05-09 21:53
- 2024-05-08 18:01
The 3 Best Bargain Stocks to Buy in May 2024(Investorplace)
- 2024-05-07 08:00
- 2024-05-06 20:00
- 2024-05-05 18:00
- 2024-05-02 16:04
- 2024-05-02 04:04
- 2024-04-30 22:05
- 2024-04-30 08:00
- 2024-04-29 20:00
- 2024-04-25 00:03
- 2024-04-25 00:03
- 2024-04-23 16:55
ImmunityBio's bladder cancer therapy wins FDA approval(Yahoo Finance Video)
- 2024-04-22 21:56
- 2024-04-22 09:56
- 2024-04-18 23:02
12 Most Shorted Stocks in 2024(Insidermonkey)
- 2024-03-19 09:53
- 2024-03-13 20:45
- 2024-03-06 09:00
- 2024-03-05 20:00
- 2024-03-05 09:00
- 2024-03-04 20:00
- 2024-02-21 09:00
- 2024-02-20 20:00
- 2024-02-13 05:17
ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?(Simply Wall St.)
- 2024-02-05 09:00
- 2024-02-04 20:00
- 2024-01-02 18:10
- 2024-01-02 06:00
Page 1 of 4
previousnext